In this study, we provide additional evidence that TWEAK can have diverse effects on cancer cells, in this case invasive capacity, even though all the evidence to date indicates that this cytokine acts via binding to a sole signaling-competent receptor (Fn14) [60, 61]. The gene discussed is TNFRSF12A; the disease is cancer.